About sellas life sciences group - SLS
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
SLS At a Glance
SELLAS Life Sciences Group, Inc.
Times Square Tower
New York, New York 10036
| Phone | 1-646-200-5278 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -30,881,000.00 | |
| Sector | Health Technology | Employees | 15 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SLS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.129 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.608 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.02 |
SLS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,058,733.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SLS Liquidity
| Current Ratio | 1.717 |
| Quick Ratio | 1.717 |
| Cash Ratio | 1.471 |
SLS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -237.227 |
| Return on Equity | -4,147.884 |
| Return on Total Capital | -295.06 |
| Return on Invested Capital | -2,566.999 |
SLS Capital Structure
| Total Debt to Total Equity | 10.576 |
| Total Debt to Total Capital | 9.564 |
| Total Debt to Total Assets | 5.099 |
| Long-Term Debt to Equity | 4.828 |
| Long-Term Debt to Total Capital | 4.367 |